# OnCo record nct07566156 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07566156/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07566156", "NCT07566156" ;
  schema:name "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)"@en ;
  schema:description "A phase 3 trial of Enfortumab vedotin, Cisplatin, Mitomycin C, Gemcitabine and Pembrolizumab in bladder & urothelial cancer, run by Astellas Pharma Global Development, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07566156/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07566156> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-05-11" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/mitomycin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/pfizer/> .